Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 4 1

Status

Completed 5Recruiting 1

Sponsor Class

OTHER 8INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

NET 6Endocrine 6Gastrointestinal 1

Conditions

Neuroendocrine Tumors 6Gastro-enteropancreatic neuroendocrine tumor 2Carcinoid Tumor 2Serotonin Syndrome 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Neuroendocrine Tumour With Carcinoid Symptoms 1Neuroendocrine Tumors in Lung 1Intestinal Obstruction 1Flushing 1Endocrine Tumors 1Diarrhea 1Carcinoma 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

Everolimus 15surufatinib 7lutetium Lu 177 dotatate 6lanreotide 6amino-acid, glucose, and electrolyte solution 5Octreotide 5Sunitinib 4Data Collection 4pasireotide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2pembrolizumab 2fosbretabulin 2arginyllysine 2Temozolomide 2Paclitaxel 2PM 01183 2Irinotecan 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1pelcitoclax 1liposomal doxorubicin 1gadoteridol 1gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Neuroendocrine Tumors × lanreotide × Clear all
NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT00842348 2022-10-12

NET729

Ipsen

Phase 3 Completed
89 enrolled 9 charts
EndocrineNET

Neuroendocrine Tumors

NCT00326469 2020-11-05

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Ipsen

Phase 2 Completed
30 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02698410 2020-10-01

ATLANT

Ipsen

Phase 2 Completed
40 enrolled 17 charts
EndocrineNET

Neuroendocrine Tumors

NCT02075606 2019-06-07

CALM-NET

Ipsen

Phase 4 Completed
50 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡